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Assessment of metal concentrations in the SOD1G93A mouse model of
amyotrophic lateral sclerosis and its potential role in muscular denervation,
with particular focus on muscle tissue
Abstract
Background: Amyotrophic lateral sclerosis (ALS) is among the most common of the motor neuron diseases,
and arguably the most devastating. During the course of this fatal neurodegenerative disorder, motor neurons
undergo progressive degeneration. The currently best-understood animal models of ALS are based on the
over-expression of mutant isoforms of Cu/Zn superoxide dismutase 1 (SOD1); these indicate that there is a
perturbation in metal homeostasis with disease progression. Copper metabolism in particular is affected in the
central nervous system (CNS) and muscle tissue.
Methods: This present study assessed previously published and newly gathered concentrations of transition
metals (Cu, Zn, Fe and Se) in CNS (brain and spinal cord) and non-CNS (liver, intestine, heart and muscle)
tissues from transgenic mice over-expressing the G93A mutant SOD1 isoform (SOD1 G93A), transgenic mice
over-expressing wildtype SOD1 (SOD1WT) and non-transgenic controls.
Results: Cu accumulates in non-CNS tissues at pre-symptomatic stages in SOD1G93A tissues. This
accumulation represents a potentially pathological feature that cannot solely be explained by the over-
expression of mSOD1. As a result of the lack of Cu uptake into the CNS there may be a deficiency of Cu for
the over-expressed mutant SOD1 in these tissues. Elevated Cu concentrations in muscle tissue also preceded
the onset of symptoms and were found to be pathological and not be the result of SOD1 over-expression.
Conclusions: It is hypothesized that the observed Cu accumulations may represent a pathologic feature of ALS,
which may actively contribute to axonal retraction leading to muscular denervation, and possibly significantly
contributing to disease pathology. Therefore, it is proposed that the toxic-gain-of-function and dying-back
hypotheses to explain the molecular drivers of ALS may not be separate, individual processes; rather our data
suggests that they are parallel processes.
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Abstract 33 
Background: Amyotrophic lateral sclerosis (ALS) is among the most common of the 34 
motor neuron diseases, and arguably the most devastating. During the course of this 35 
fatal neurodegenerative disorder, motor neurons undergo progressive degeneration. 36 
The currently best-understood animal models of ALS are based on the over-37 
expression of mutant isoforms of Cu/Zn superoxide dismutase 1 (SOD1); these 38 
indicate that there is a perturbation in metal homeostasis with disease progression. 39 
Copper metabolism in particular is affected in the central nervous system (CNS) and 40 
muscle tissue. 41 
Methods: This present study assessed previously published and newly gathered 42 
concentrations of transition metals (Cu, Zn, Fe and Se) in CNS (brain and spinal cord) 43 
and non-CNS (liver, intestine, heart and muscle) tissues from transgenic mice over-44 
expressing the G93A mutant SOD1 isoform (SOD1
G93A
), transgenic mice over-45 
expressing wildtype SOD1 (SOD1
WT
) and non-transgenic controls. 46 
Results: Cu accumulates in non-CNS tissues at pre-symptomatic stages in SOD1
G93A
 47 
tissues. This accumulation represents a potentially pathological feature that cannot 48 
solely be explained by the over-expression of mSOD1. As a result of the lack of Cu 49 
uptake into the CNS there may be a deficiency of Cu for the over-expressed mutant 50 
SOD1 in these tissues. Elevated Cu concentrations in muscle tissue also preceded the 51 
onset of symptoms and were found to be pathological and not be the result of SOD1 52 
over-expression. 53 
Conclusions: It is hypothesized that the observed Cu accumulations may represent a 54 
pathologic feature of ALS, which may actively contribute to axonal retraction leading 55 
to muscular denervation, and possibly significantly contributing to disease pathology. 56 
Therefore, it is proposed that the toxic-gain-of-function and dying-back hypotheses to 57 
 3 
explain the molecular drivers of ALS may not be separate, individual processes; 58 
rather our data suggests that they are parallel processes.  59 
 60 
Keywords: ALS, Copper, Spinal Cord, Brain, Muscle, Distal Motor Neuropathy; 61 
 62 
Introduction 63 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, which leads to 64 
selective motor neuron (MN) death, and is ultimately fatal (Redler and Dokholyan, 65 
2012; Rowland and Shneider, 2001). The degeneration results in progressive muscular 66 
paralysis, affecting mobility, speech, and respiration (Hardiman et al., 2011); most 67 
patients die within 5 years from diagnosis (Robberecht and Philips, 2013). Most ALS 68 
cases are described as sporadic, but around 5 - 10% are familial (Rowland and 69 
Shneider, 2001) and associated with a variety of Mendelian-inherited mutations 70 
(Robberecht and Philips, 2013). 71 
 72 
The first gene identified to be mutated in familial ALS encodes Cu/Zn superoxide 73 
dismutase 1 (SOD1), accounting for ~20% of familial ALS cases (Rosen et al., 1993). 74 
The specific mechanisms leading to the selective degeneration of MNs remains 75 
unclear, with a variety having been proposed to play a role, such as oxidative stress, 76 
glutamate-mediated excitotoxicity, protein aggregation and transition metal-induced 77 
toxicity (Cozzolino et al., 2008). Toxicity induced by mutant SOD1 (mSOD1) is 78 
likely to be the result of a toxic-gain-of-function (Bruijn et al., 1998; Gurney et al., 79 
1994), driven by the increased destabilization of the protein, which causes it to 80 
misfold and aggregate. To-date the most studied mouse model of ALS is the 81 
transgenic mouse that overexpresses the SOD1-G93A mutation (SOD1
G93A
). In this 82 
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model, human SOD1 harboring the G93A mutation is overexpressed (20-24 fold 83 
higher expression than endogenous murine SOD1) (Gurney et al., 1994). This mouse 84 
model recapitulates many features of human ALS, including axonal and 85 
mitochondrial dysfunction, progressive neuromuscular dysfunction, protein 86 
aggregation and MN loss (Bruijn et al., 1997; Gurney et al., 1994; Ripps et al., 1995). 87 
Results from experimental data suggest that the binding of Cu and Zn by mSOD1 may 88 
be defective (Carri et al., 1994; Eum and Kang, 1999; Hayward et al., 2002). 89 
 90 
While transition metals (e.g. Cu and Zn) are crucial for the function of many metallo-91 
proteins (e.g. SOD1), they can be toxic at high concentrations (Gaetke and Chow, 92 
2003; Jomova and Valko, 2011; Valko et al., 2005), and their uptake, distribution, 93 
storage and excretion are therefore tightly controlled (Hare et al., 2013; Tapiero et al., 94 
2003). The role of metals in the pathogenesis of certain neurodegenerative diseases 95 
(i.e. Cu, Fe and Al in Alzheimer’s disease (Greenough et al., 2013; House et al., 2012; 96 
Kaden et al., 2011; Shore et al., 1984)) is becoming evident; however, the particular 97 
role of Cu and Zn homeostasis in the pathology of ALS remains unclear (Roberts et 98 
al., 2014).  99 
 100 
Findings in the G93A mouse model of ALS indicate that there is a pathologic 101 
perturbation in Cu metabolism. While the accumulation and/or depletion of metals in 102 
different tissues reported in the literature are inconsistent, overall there appears to be 103 
accumulation in tissues of diseased mice. Tissues associated with the autonomic 104 
nervous system (ANS) have been shown to accumulate Cu and Zn (Enge et al., 2017; 105 
Hilton et al., 2016), with muscle tissue demonstrating pre-symptomatic increases in 106 
concentrations (Enge et al., 2017). Results from central nervous system (CNS) tissues 107 
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indicate accumulation of Cu in the spinal cord (Li et al., 2006; Tokuda et al., 2015, 108 
2014, 2013, 2008) at single time points, as well as over time (Tokuda et al., 2009, 109 
2007). Brain tissue showed a similarly varied behavior with studies reporting both 110 
elevated concentrations (Hilton et al., 2016), or no change to healthy controls (Enge et 111 
al., 2017; Lelie et al., 2011; Li et al., 2006; Tokuda et al., 2009, 2007). These changes 112 
in Cu and Zn concentrations have been postulated to play an important role in the 113 
toxic-gain-of-function associated with mSOD1 (Borchelt et al., 1994; Hilton et al., 114 
2015). Two major strategies to alleviate symptoms of ALS that involve metals have 115 
been proposed. These are based on either reducing the general availability of Cu 116 
through the application of Cu chelators (i.e. Trietine or D-penicillamine), which has 117 
been shown to prolong survival of SOD1
G93A 
mice (Hottinger et al., 1997; Nagano et 118 
al., 2003); or the application of a synthetic Cu-containing therapeutic agent (Cu
II
-119 





 mice (Hilton et al., 2017; McAllum et al., 2013; Roberts et 121 
al., 2014; Soon et al., 2011; Williams et al., 2016). 122 
 123 
In SOD1, Cu and Zn ions are crucial for its function: Zn provides structural stability, 124 
while Cu is essential for the protein’s catalytic activity. In SOD1 mouse models of 125 
ALS, mutant SOD1 accumulates in a Cu-deficient form (Lelie et al., 2011; Roberts et 126 
al., 2014; Williams et al., 2016). This partially metalated SOD1 is proposed to lead to 127 
aggregation and toxicity (Bruijn et al., 1998; Gurney et al., 1994; Roberts et al., 128 
2014). Treatment of mice with the synthetic Cu-containing therapeutic agent 129 
Cu
II
(atsm) converts the partially metalated SOD1 into holo SOD1 through the 130 
delivery of Cu (Roberts et al., 2014), improving the phenotype significantly (Lelie et 131 
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al., 2011; Roberts et al., 2014; Williams et al., 2016). This points towards a 132 
misbalance of bioavailability and demand for Cu in the CNS (Hilton et al., 2016). 133 
 134 
The potential role of metals as well as muscle tissue (Gonzalez de Aguilar et al., 135 
2008; Luo et al., 2013; Xiao et al., 2015) in ALS pathology has recently gathered 136 
further attention. In addition to the involvement of metals in binding to SOD1, recent 137 
research has suggested that toxic accumulation of metals in muscle tissue may also 138 
play a role in ALS pathology (Enge et al., 2017). With pathological hallmarks that 139 
include the destruction of the neuromuscular junction (NMJ) and axonal retraction 140 
preceding MN death (Zhou et al., 2015), ALS could be described as a distal motor 141 
neuropathy (Enge et al., 2017; Fischer et al., 2004; Frey et al., 2000; Kiernan et al., 142 
2011).  143 
 144 
In this study concentrations of transition metals in transgenic mutant SOD1 mice 145 
(G93A) and non-transgenic controls were assessed. Through the longitudinal 146 
comparison of diseased and healthy CNS and non-CNS tissues, this research sought to 147 
expand current knowledge on the role and presence of transition metals in the 148 
pathology of ALS. Metal accumulations in muscle tissue were assessed for their 149 




This study used two types of transgenic over-expression models, SOD1
G93A
 and 154 
SOD1
WT
; only female mice were used in this work. The SOD1
G93A 
mouse model of 155 
ALS expressed the G93A mutant form of human SOD1 (B6SJL-156 
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Tg(SOD1*G93A)1Gur/J)(Gurney et al., 1994) (Jackson Laboratory, ME, USA), 157 
backcrossed onto a black 6 background. Healthy controls for these mice were non-158 
transgenic littermates (NTG
UOW
). These mice were bred at Australian Bioresources 159 
(Mossvale, AU) in accordance with the approved University of Wollongong ethics 160 
clearance (AE14/28). At ages 30, 60, 90 and 120 (±2) days, capturing the 161 
characteristic disease progression (Olsen et al., 2001), mice were euthanized by CO2 162 
asphyxiation and blood collected via puncturing of the left ventricle. The mice were 163 
not perfused and following blood collection immediately dissected and tissue samples 164 
(brain, spinal cord, liver, intestine, heart and muscle) were snap frozen in liquid 165 
nitrogen. Muscle tissue was samples of Quadriceps femoris from both legs and 166 
intestine samples were 2 cm sections immediately following the stomach.  167 
 168 
The second type of mouse model used was SOD1
WT
 mice, which overexpress the non 169 
mutated form of human SOD1 (B6SJL-Tg(SOD1)2Gur/J) (Gurney et al., 1994) 170 
(Jackson laboratories). Healthy controls were non-transgenic littermates (NTG
UCL
). 171 
Mice were bred at University College London - Biological Services (London, UK) in 172 
accordance with the Guide for the Care and Use of Laboratory Animals as adopted by 173 
the US National Instituted of Health and under license from the UK Government 174 
(Animals and Scientific procedures) Act 1986 (Amended Regulations 2012), 175 
following ethical approval from the University College London Institute of 176 
Neurology. The samples taken from this mouse model were brain, spinal cord and 177 
muscle tissue (Quadriceps femoris) samples. These samples were collected at 60 and 178 
90 d to assess if the previously observed increase in Cu concentration in diseased 179 
tissue (Enge et al., 2017) is the result of the over expression of the mSOD1 or presents 180 
a pathologic feature, independent of mSOD1 over-expression. 181 
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 182 
Samples of DORM-2 dogfish muscle, certified reference material of the National 183 
Research Council Canada (CRM, NRCC), were used to test the completeness and 184 
accuracy of the sample digestion protocol (Enge et al., 2016). 185 
 186 
Analytical techniques 187 
Sample digestion 188 
Mouse tissues and DORM-2 aliquots were weighed and pre-digested in MARSXpress 189 
20 mL PFA vessels in a 2.5:1 mixture of 15 M Ultrapur® HNO3 (Merck) and 190 
Ultrapur® 30% H2O2 (Merck) for 30 min. Pre-digested samples were completely 191 
digested using MARS6 (CEM Corporation, North Carolina, USA) microwave 192 
systems. Temperature was ramped to 210 ºC over 15 min and held constant for 150 193 
min to ensure all organic carbon was driven off as gaseous CO2. For quality control 194 
purposes, one blank (acid only) and two DORM-2 aliquots were added to each 195 
digestion batch. Recovery of elements (Cu, Fe, Zn and Se) from the DORM-2 196 
certified reference material was used to validate that the digestion of biological 197 
samples was complete (Table 1). Selenium concentrations were only determined in 198 
liver, intestine and heart tissues. 199 
 200 
Table 1 – Recoveries of select metals from DORM-2 (CRM, NRCC), in mg kg
-1
, 201 
during processing of samples  202 
Element Certified Value 2SD Measured Value 2SD Recovery (%) N 
Cu 2.34 0.16 2.4 0.4 104 21 
Fe 142 10 133 31 94 21 
Zn 25.6 2.3 26 10 109 21 
Se 1.40 0.09 1.4 0.2 101 8 
 203 
Elemental Concentrations  204 
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Copper, Fe, Zn and Se concentrations were determined using a Thermo Scientific 205 
iCAP-Q quadrupole-inductively coupled plasma-mass spectrometer (Q-ICP-MS) at 206 
the Wollongong Isotope Geochronology Laboratory, University of Wollongong 207 
(WIGL, UOW). The concentrations were quantified using a multi-element standard 208 
external calibration curve; long-term instrument drift was corrected using a 50 ppb Ga 209 
solution as an internal standard. Accuracy of the measurements was assessed through 210 
the analysis of the DORM-2 CRM, which yielded recoveries of 104% for Cu, 94% for 211 
Fe, 109% for Zn and 101% for Se (Table 1). Total procedure blanks were assessed as 212 
<4 ng Cu, <9 ng Fe, <18 ng Zn, and <13 ng Se, and deemed negligible (<0.13% for 213 
Cu, Zn and Fe; <2% for Se) compared to the total amount processed (see 214 
supplementary tables). 215 
 216 
Statistical Methods 217 
Statistical analysis was conducted using the statistical program R v3.4.2 (R Core 218 
Team, 2016). Prior to analysis, outliers were removed using the median average 219 
deviation (3*mad). Any measurements outside 3*mad were considered to be 220 
measurement artifacts or the result of contamination. Transgenic SOD
WT
 muscle 221 
samples were analysed qualitatively, due to the low sample number. Data were 222 
analyzed using linear regression models with disease state and time used as 223 
independent variables and Cu, Fe, Zn and Se concentrations, as dependent variables. 224 
Likelihood ratio tests were used to determine which independent variables were 225 
significant (Barr et al., 2013). The assumptions of the linear regression model were 226 
checked (linearity, independence, normality and equality of variance), including 227 




Peripheral tissues 231 
Tissues controlled by the ANS, i.e. the liver, intestine and heart, demonstrate a 232 
significant difference in Cu concentration (p < 0.0005) between the SOD1
G93A
 and 233 
healthy controls (Figure 1A-C), which is evident starting at 30 d, with concentrations 234 
in heart and liver increasing over time in the diseased tissues, while they remained 235 
relatively constant in the intestine. Zinc concentrations show a similar behaviour to 236 
Cu: they vary significantly between SOD1
G93A
 and healthy controls in heart and liver 237 
tissue (p < 0.0005), and intestine (p = 0.03) (Figure 1D-F) starting at 30 d. In heart 238 
and liver, the Zn concentrations increase over time, while concentrations in intestine 239 
remain largely constant. In contrast to Cu and Zn, Fe concentrations only vary 240 
significantly between the diseased and healthy liver (p = 0.05) and the intestine (p = 241 
0.006) tissue (Figure 2 A-C), and over time in liver (p < 0.0005) and intestine (p = 242 
0.001). Concerning Se concentrations, only intestine was found to show a significant 243 
difference between healthy and diseased tissue (p = 0.04), while Se concentrations in 244 
heart (p = 0.002), liver and intestine (p = 0.0005) changed over time (Figure 2D-F). 245 
 246 
Muscle tissue (Quadriceps) 247 
As previously shown (Enge et al., 2017), Cu (p < 0.0005),  Zn (p < 0.0005) and Fe (p 248 




 mice (Figure 3). 249 
Muscle tissues from mice that overexpress the SOD1
WT
 were collected at 60 d and 90 250 
d and tissues from non-transgenic littermates from the same colony were collected at 251 
90 d of age (Figure 4). The concentrations of Cu, Zn and Fe in the SOD
WT
 samples 252 
are in agreement with results from muscle tissue collected from non-transgenic mice 253 
from a different colony (NTG
UOW




 tissues match well these found in NTG
UOW
 non-transgenic controls (Figure 255 
3). 256 
 257 
Central nervous system tissues 258 
It was previously shown that there is no significant difference between brain and 259 




 mice in Cu, Zn and Fe concentrations 260 
(Enge et al., 2017). Samples from mice over-expressing SOD1
WT
 and non-transgenic 261 
littermates from the same colony (NTG
UCL
) were collected at 60 and 90 d of age, and 262 





mice from a different colony (Supplementary Figure 1). 264 
 265 
DISCUSSION 266 
Accumulation of Cu and Zn in tissues controlled by the ANS 267 
Tissues controlled by the ANS play an as yet unknown role in the development of 268 
ALS. The accumulation of Cu in the heart and liver could either be pathological and 269 
driven by ALS, or the result of the over-expression of SOD1 in the mouse model. As 270 
the mouse model of ALS overexpresses (20 - 24 times) human SOD1 harboring the 271 
G93A mutation (Gurney et al., 1994), overexpression of the protein could result in it 272 
acting as a Cu sink (Tokuda and Furukawa, 2016). However, if this were the case a 273 
uniform offset with regards to the Cu concentration in tissues from SOD1
G93A
 mice 274 
compared to the non-transgenic mice would be expected (similar to that observed for 275 
the intestine where concentrations did not change significantly over time).  A lack of 276 
increases of SOD1 concentration with time in spinal cord and brain of various mouse 277 
models of ALS was observed and attributed to reflecting high-level relative steady-278 
states (Jonsson et al., 2006). Though work by Turner et al. (2003) has shown age-279 
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dependent accumulation of hSOD1 in the lumbar spinal cord, the sciatic nerve, and 280 
the gastrocnemius muscle. In our work (Enge et al., 2017) it was acknowledged that 281 
differences in Cu and Zn concentration between the SOD1
G93A
 and non-transgenic 282 
mice in muscle tissue could be due to over-expression of human SOD1. Here, 283 
observations of a lack of elevated concentrations in Fe and Se (Figure 2) point 284 
towards a great contribution of over-expressed SOD1 to the Cu accumulation. This 285 
accumulation was also reported in previous work (Tokuda et al., 2013): in spinal cord 286 
tissue of SOD1
WT
 mice (over-expression of wild-type SOD1) and SOD1
G93A
 mice Cu 287 
concentrations were elevated (up to 3.2-fold) compared to non-transgenic controls. 288 
Furthermore, Cu concentrations in spinal cord were significantly elevated in 289 
SOD1
G93A
 samples compared to SOD1
WT
 samples (Tokuda, 2017). This indicates that 290 
at least part, if not all of the accumulation of Cu and Zn in these tissues could be 291 
attributable to SOD1 over-expression. However, the distinct accumulation of Cu in 292 
heart and liver over time (Figure 1) compared to controls may represent disease 293 
pathology: previously it was found that in SOD1
G93A
 spinal cord tissue, Cu was bound 294 
to copper-binding proteins other than SOD1 and this increased over time (Tokuda et 295 
al., 2013). Accumulation of Cu in cupro-proteins besides SOD1 may therefore 296 
contribute to the observed signal.  The observation of a subtle age-dependent increase 297 
of hSOD1 in the gastrocnemius muscle (Turner et al., 2003) could though indicate 298 
that a large proportion if not all of the observed metal accumulation is a result of 299 
SOD1 accumulation with age. The lack of SOD1 concentration measurements here 300 
presents a limitation to the conclusions that can be drawn. Without tissue-matched 301 
measurements from mice that overexpress SOD1
WT
, or determination of SOD1 302 
concentrations, estimation of how much of the observed increase in Cu concentration 303 
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is attributable to the over-expression of SOD1 in peripheral system tissues remains 304 
uncertain.  305 
 306 
Zinc concentrations were found to be significantly elevated in all three tissues (liver, 307 
heart and intestine) and their concentrations in heart and liver increase over time 308 
(Figure 1D-F). Similar to Cu, increased concentration of Zn in heart and liver of 309 
SOD1
G93A
 mice are likely to be related to the over-expression of SOD1, as other 310 
elements (Fe and Se) were not increased (Figure 2). Another factor may also 311 
contribute: work using spinal cord tissue from SOD1
G93A
 mice showed an 312 
accumulation of Zn not only in the zinc-binding site of SOD1, but also suggested an 313 
increase of Zn binding in other Zn binding proteins (Tokuda et al., 2013). The 314 
increase in Zn concentration was also statistically significant in the intestine; the 315 
difference is lower and relatively constant over time.  316 
 317 
While the accumulation of Cu and Zn in these tissues precede disease pathology and 318 
symptoms, coinciding with initial protein aggregation at 30 d (Gould et al., 2006) 319 
(Table 2), the specific binding of the metal(s) to SOD1 has to be further scrutinized. 320 
 321 
Table 2 – Typical ALS symptoms and features in transgenic SOD1 mice 322 
Feature/symptom Average time of 
onset (d) 
Reference 
Initial protein aggregation 30 (Gould et 
al., 2006) 
Selective neuromuscular junction degeneration 47 (Fischer et 
al., 2004) 
Maximum running speed reduced 52 (Veldink et 
al., 2003) 
Reduction of blood flow through the spinal cord 60 (Zhong et 
al., 2008) 
Axonal loss prominent 80 (Fischer et 
al., 2004) 
Significant motor neuron loss 100 (Fischer et 
al., 2004; 
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Seki et al., 
2007) 
Onset of paralysis 100 (Chiu et al., 
1995) 
 323 
Lack of up-regulation of Cu transport into CNS 324 
Previously no increase in Cu and Zn concentrations was found in the CNS (Enge et 325 
al., 2017); in this work we show these do increase in non-CNS tissues (Figure 1). This 326 
could be the result of the non-uniform expression of mSOD1 in various tissues. 327 
Results in humans (Human Protein Atlas, 2017) as well as in the SOD1
G37R
 (Hilton et 328 
al., 2016) and SOD1
G93A
 (Gajowiak et al., 2016) mouse models  have shown that 329 
SOD1 protein expression varies between tissues; SOD1
G37R
 CNS tissues expressed 330 
much greater amounts of SOD1 compared to peripheral nervous system tissues 331 
(Hilton et al., 2016). In tissues from SOD1
G93A
 mice, higher amounts of SOD1 were 332 
reported in spinal cord compared to liver and muscle (Gastrocnemius) (Gajowiak et 333 
al., 2016).  Thus, if Cu and Zn concentrations reflected the amount of SOD1 present, 334 
it would be expected that CNS tissues would have higher concentrations of Cu and Zn 335 
compared to other tissues. The origin for the discrepancy in Cu and Zn concentrations 336 
between CNS and non-CNS tissues is therefore more likely to be the response of the 337 
blood-CNS barriers. While an increased Cu requirement in the CNS, due to the SOD1 338 
over-expression, may not be met (Hilton et al., 2016), it is unclear why Zn 339 
concentrations are not elevated.  340 
 341 
Our results show an accumulation of Cu and other metals in the heart and liver tissue 342 
compared to the CNS, as well as compared to non-transgenic controls (Enge et al., 343 
2017; Hilton et al., 2016). Blood of ALS patients was shown to not accumulate Cu 344 
and Zn, compared to controls (Garzillo et al., 2014; Kapaki et al., 1997; Nagata et al., 345 
1985; Pamphlett et al., 2001; Roos et al., 2013). This agrees with our previous 346 
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findings in the SOD1
G93A
 mouse (Enge et al., 2017). Blood carries a large amount of 347 
the total body Cu, which can be regarded as a theoretically infinite pool for the 348 
individual compartments. The observed increases in concentration in tissues such as 349 
heart and liver in the SOD1
G93A
 mice, despite no change in blood (Enge et al., 2017), 350 
suggests that acquisition of Cu from the liver into the blood does not vary. Overall the 351 
increased demand for Cu in the organism due to higher mSOD1 levels in these tissues 352 
is satisfied. Copper concentrations in the heart, liver and intestine may therefore serve 353 
as an additional proxy for disease in the SOD1
G93A
 mouse model of ALS. 354 
 355 
The lack of an increase in Cu concentration in the CNS may reflect a disconnect 356 
between the rate of Cu uptake and Cu requirement (Hilton et al., 2016) as a response 357 
to the over-expression of mSOD1. Recent results have shown that the amount of Cu 358 
in both brain and spinal cord tissue of the SOD1
G37R
 mouse model is 359 
disproportionately small compared to the amount of SOD1 protein expressed (Hilton 360 
et al., 2016). This indicates that as well as a generally slower turnover, Cu transport 361 
into the CNS is not up-regulated to satisfy the increased Cu requirement due to 362 
mSOD1 over-expression. This effectively ‘starves’ the over-expressed mSOD1 363 
(Figure 4) (Hilton et al., 2016). As a result, the protein could be destabilized, making 364 
it aggregation-prone (Lelie et al., 2011). The result could be MN death through direct 365 
toxicity of the partially metalated SOD1 (Gil-Bea et al., 2017; Roberts et al., 2014).  366 
 367 
Pathological accumulation of Cu in muscle tissue may contribute to ALS development 368 
Muscle tissue (Gonzalez de Aguilar et al., 2008; Luo et al., 2013; Xiao et al., 2015), 369 
and other (neighbouring) cell types (Boillée et al., 2006) may play a significant role in 370 
the development of ALS pathology. Distinct and rapid muscle atrophy caused by MN 371 
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death is a pathologic feature of ALS. Skeletal muscle comprises ~40% of whole body 372 
lean mass and, combined with bone, makes up ~50% of total body Cu in humans 373 
(Evans, 1973). We previously showed consistently elevated metal concentrations in 374 
SOD1
G93A
 muscle tissue compared to samples from non-transgenic animals (Enge et 375 
al., 2017), in accordance with previous findings (Hilton et al., 2016). These increases 376 
of Cu and Zn concentrations precede the onset of disease symptoms (Figure 4A-B), 377 
while Fe trails them (Figure 4C) (Enge et al., 2017). We hypothesized that this 378 
observed accumulation could be the result of the over-expression of mSOD1 in the 379 
SOD1
G93A
 mouse model and that further testing, involving tissues from mice that 380 
over-express SOD1
WT
 was necessary to determine whether a pathologic accumulation 381 
of Cu occurred in muscle tissue. 382 
 383 
Here, Cu, Zn and Fe concentrations measured in samples from mice over-expressing 384 
wild type SOD1 were similar to those found in tissues from non-transgenic controls 385 
(Figure 4A-C). This is in agreement with results from a previous study comparing Cu 386 
in spinal cord tissues from mice over-expressing wild-type SOD1 and non-transgenic 387 
controls (Tokuda et al., 2009). Since the accumulation of these metals in muscle tissue 388 
is not related to SOD1 over-expression, we contend that it represents a pathological 389 
feature of ALS that warrants further investigation, particularly as the accumulation of 390 
Cu is pre-symptomatic (Figure 4A). While the method applied here does not enable us 391 
to determine the origin of the accumulation, several hypotheses regarding its 392 
involvement in ALS pathology are presented below:  393 
 394 
First, as previously proposed (Enge et al., 2017), Cu accumulation may result in 395 
toxicity at the NMJ and the onset of ALS as a distal motor neuropathy that proceeds 396 
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via a ‘dying-back’ mechanism (Enge et al., 2017; Fischer et al., 2004; Frey et al., 397 
2000; Kiernan et al., 2011). In this case distal axonal degeneration precedes neuronal 398 
degeneration, whereby axons and NMJs are affected early and the MN withdraws due 399 
to perturbations arising from muscle tissue (Zhou et al., 2015). This contrasts the 400 
toxic-gain-of-function and ‘dying-forward’ hypotheses in which denervation results 401 
from the CNS. To understand the potential role of muscular Cu as a trigger for axonal 402 
denervation, its location within the tissue must be considered: Cu may reside in the 403 
cytosol or extracellular space. In the cytosol, it could lead to increased reactive 404 
oxygen species (ROS)-related stress and ultimately cellular damage and apoptosis 405 
(Linder, 1991). However, Cu is unlikely to be present as a free ion, as this would 406 
trigger an anti-oxidant response through SOD1 and other protective mechanisms, in 407 
order to reduce its impact. Mechanisms to protect against Cu toxicity include the 408 
intrinsic stress response of the heat shock proteins (e.g. heat shock protein 70) (Urani 409 
et al., 2001), which can be triggered by sub-lethal concentrations of Cu. Additionally, 410 
the metal-responsive transcription factor 1 (MTF-1) (Balamurugan and Schaffner, 411 
2006) acts under both high and low Cu concentrations to control the expression of 412 
metallothioneins and other components (Cu importer/transporter 2) that control Cu 413 
homeostasis. Copper in the extracellular space can bind to a variety of proteins, 414 
including ceruloplasmin, extracellular SOD1, extracellular metallothionein and 415 
albumin (Linder and Hazegh-Azam, 1996). The work presented here is limited to 416 
organ-level resolution and therefore does not provide any insight into how Cu 417 
accumulates in tissues, including whether it is located inside or outside cells, or both. 418 
 419 
Second, the accumulation of Cu in muscle tissue may be the consequence of 420 
hypermetabolism. Increases in energy expenditure are intrinsically linked to ALS 421 
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progression, preceding axonal retraction and denervation (Dupuis et al., 2004; Dupuis 422 
and Loeffler, 2009; Ferri and Coccurello, 2017). Even though previous work has 423 
shown that mitochondrial defects precede the onset of MN loss (Basun et al., 1991; 424 
Jaarsma et al., 2000; Kong and Xu, 1998), specific mechanisms and causal links 425 
between hypermetabolism and mitochondrial dysfunction remain largely unknown. 426 
  427 
 428 
Mitochondrial respiration produces electrons, which may escape the electron transport 429 
chain to induce the formation of reactive oxygen species (ROS) (Adam-Vizi and 430 
Chinopoulos, 2006; Liemburg-Apers et al., 2015; Murphy, 2009). Mitochondrial 431 
dysfunction, including muscle tissue, has been identified as one of the key features of 432 
ALS (Leclerc et al., 2001); aggregated, swollen, vacuolated and fragmented 433 
mitochondria, as a possible result of mSOD1 interaction (Pickles et al., 2016), are 434 
able to explain other pathological features such as oxidative stress, glutamate 435 
excitotoxicity and apoptosis (Abel et al., 2012; Faes and Callewaert, 2011; Martin, 436 
2011; Smith et al., 2017). It was suggested that dys-regulation of Cu homeostasis may 437 
play a substantial role in the development of the mitochondrial defects associated with 438 
ALS (Son et al., 2007).  439 
 440 
The observed Cu accumulation in muscle tissue may be the result of more than one 441 
mechanism, whereby the initial increase could result from an unidentified process that 442 
also increases ROS production. Increases in ROS could stimulate glucose uptake, 443 
which in return could stimulate ROS production leading to a positive feedback loop 444 
(Liemburg-Apers et al., 2015). Simultaneously, Cu transport into mitochondria could 445 
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be up regulated to meet the demand of cellular respiration, resulting in the observed 446 
hypermetabolism and overall accumulation of Cu in the tissue. 447 
 448 
An updated view on the role of Cu in muscle tissue in ALS 449 
The specific role of accumulated Cu in muscle tissue associated with ALS pathology 450 
remains unclear. The data presented here shows an increase in metal concentrations in 451 
muscle tissues of the SOD1
G93A
 mouse model over time. This is interpreted as a 452 
pathological process (Figure 5C), which may result in both a toxic-gain-of-function 453 
(partially metalated SOD1 aggregates are toxic and lead to axonal retraction), as well 454 
as a dying-back mechanism (e.g. accumulation of insoluble mSOD1 aggregates and 455 
glutamate toxicity result in ALS presenting as a distal axonal retraction that precedes 456 
death of MNs [see Ref (Dadon-Nachum et al., 2011) for a comprehensive review]) of 457 
ALS onset and progression. The unifying feature in both these mechanisms is Cu, be 458 
it the above-described lack of up-regulation in the CNS or the apparent accumulation 459 
in ANS tissues. We therefore propose a new theoretical model here, in which both the 460 
toxic-gain-of-function and the dying-back hypotheses could be occurring in parallel, 461 
to explain the mechanisms of ALS pathology (Figure 5C). The relative proportion to 462 
which each process contributes to the end result of muscular denervation remains 463 
unclear.  464 
 465 
The model proposed here combines findings of general Cu accumulation in peripheral 466 
tissues, specifically muscle tissue, and lack of up-regulation of Cu in the CNS. It is 467 
proposed that there are separate processes (Figure 5A, B) associated with Cu (either 468 
as a trigger or consequence), whose specific distribution on an organ level we have 469 
tested (Figure 5C). This specific distribution may contribute to the development of 470 
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ALS in these mice (see above). Furthermore, the model explains why Cu chelators 471 
(Hottinger et al., 1997; Nagano et al., 2003), as well as synthetic Cu-containing 472 
therapeutic agent (Roberts et al., 2014) likely act to prolong the survival of SOD1 473 
mouse models. In addition to the transformation of labile intermediate forms of SOD1 474 
into apo-SOD1, (Roberts et al., 2014) Cu chelators may also remove some generally 475 
available Cu to prevent its accumulation in tissues. Simultaneously the synthetic Cu-476 
containing therapeutic agent Cu
II
(atsm), which is able to readily cross the BBB, was 477 
found to deliver Cu to mSOD1 so it is in a (stable) holo-SOD1 state (Hilton et al., 478 
2017; Soon et al., 2011; Williams et al., 2016). Prolonged survival (>20%) in G93A 479 
mice treated with Cu
II
(atsm) has been reported, however this lifespan is greatly 480 
extended in G93A mice co-expressing the copper chaperone for superoxide dismutase 481 
(CCS) (G93AxCCS) and treated transdermally from prenatal stages (Williams et al., 482 
2016). Even though this presents a very important milestone in finding a feasible 483 
treatment option for ALS, it is not a cure as all mice developed typical end stage 484 
motor neuron disease. Furthermore, G93AxCCS mice removed from treatment after 485 
21 days had the same life span as SOD1
G93A
 mice (Williams et al., 2016). This 486 
indicates that at least part of the toxic-gain-of-function of SOD1 resides in mSOD1 487 
being metal deficient, while pathological Cu accumulation in muscle tissue may also 488 
contribute.  489 
 490 
Based on the model we have proposed here, a treatment combining a specific Cu 491 
chelator (to prevent Cu accumulation in non-CNS tissues), and a synthetic Cu-492 
containing therapeutic agent (to deliver Cu to the CNS) could be most beneficial to 493 
treat ALS in the here assessed G93A mouse model. An application to humans with 494 
SOD1 familial ALS, and potentially other genotypes, could be beneficial as well; 495 
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even though studies on human tissue samples did not observe Cu accumulation in 496 
neither liver or kidneys (Sillevis Smitt et al., 1992), nor in brain (Gellein et al., 2003) 497 
of ALS patients compared to controls. The lack of general accumulation of Cu in 498 
human ALS patients is non conclusive at this point due to the overall limited number 499 
of studies available. Future studies should systematically assess Cu concentrations in 500 
human ALS patient organs, including muscle tissues, target tissues of ALS. 501 
Furthermore, Cu accumulation in ALS models has to further be examined as it may 502 
serve as a biomarker of disease. 503 
 504 
CONCLUSIONS 505 
The assessment of metal concentrations in several tissues from control and ALS mice 506 
showed accumulation of Cu in tissues controlled by the ANS compared to controls, 507 
which was also not observed in CNS tissues. This accumulation was identified to be 508 
pre-symptomatic. Muscle tissue showed accumulation of Cu, which was not driven by 509 
over-expression of SOD1 (Enge et al., 2017), but rather was associated with disease 510 
pathology in SOD1
G93A
 mice and was evident at pre-symptomatic stages. The results 511 
further indicate that there is a lack of Cu uptake into the brain despite the higher Cu 512 
requirement due to mSOD1 over-expression in the SOD1
G93A
 mouse model of ALS. 513 
The observed pre-symptomatic changes in metal concentrations in tissues controlled 514 
by the ANS provide further evidence for a role of metals, in particular Cu, in the 515 
development of ALS pathology. 516 
 517 
The accumulation of Cu in muscle tissue leads us to propose a revised model of the 518 
mechanisms underpinning ALS pathology, which unites the toxic-gain-of-function 519 
and dying-back hypotheses. Our model offers another explanation to elucidate the 520 
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axonal retraction of MNs in ALS, a process potentially underpinned by Cu 521 
accumulation. Further investigation into the potential applicability of metal 522 
concentrations as biomarkers for ALS is therefore warranted. Future studies should 523 
expand to study human tissues, and further establish in disease models the location 524 
and binding of Cu in ANS tissues to help further elucidate the role that Cu plays in the 525 
aetiology of ALS. 526 
 527 
LIST OF ABBREVIATIONS 528 
Ab  Albumin 529 
ALS   Amyotrophic lateral sclerosis 530 
ANS  Autonomic nervous system 531 
ATOX  Copper metal chaperone 532 
ATP7A ATPase copper transporting alpha 533 
BBB   Blood-brain-barrier 534 
BCB  Blood-cerebrospinal fluid-barrier 535 
CCS  Copper chaperone for superoxide dismutase 536 
CNS  Central nervous system 537 
COX  Cytochrome c oxidase 538 
CP  Ceruloplasmin 539 
CTR1  Copper transporter 1 540 






DMT1  Divalent metal transporter 1 543 
FUS  Fused in Sarcoma 544 
MN  Motor neuron 545 
MTF1  Metal regulatory transcription factor 1 546 
NMJ  Neuromuscular junction 547 
Q-ICP-MS Quadrupole-inductively coupled plasma-mass spectrometer 548 
ROS  Reactive oxygen species 549 
SOD1  Cu,Zn superoxide dismutase 1 550 
TDP-43 TAR DNA-binding protein 43 551 
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